Fortrea to Participate in Jefferies Global Healthcare Conference
Fortrea announced that its executive leadership team will participate in the upcoming Jefferies Global Healthcare Conference in London.
Stocks · News reference
Fortrea and Omico Announce Collaboration to Advance Precision Oncology Research
Fortrea and Australian-based Omico have entered a collaboration to connect cancer patients to biomarker-matched clinical trials.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Collaboration entre Fortrea et Omico pour faire progresser le développement de médicaments oncologiques basés sur des biomarqueurs
Fortrea, a leading global contract research organization, has announced a collaboration with Omico, Australia's leading precision oncology screening organization, to accelerate biomarker-driven oncology drug development. The partnership combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve clinical trial planning, site selection, and patient recruitment for targeted cancer therapies in Australia.
Fortrea 與 Omico 攜手合作，推動生物標記主導的腫瘤藥物開發
Fortrea, a leading Contract Research Organization (CRO), has partnered with Omico, Australia's precision oncology screening platform, to accelerate biomarker-driven cancer clinical trials in Australia. The collaboration combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve trial planning, site selection, and patient recruitment, leveraging Omico's database of over 23,000 consented patients and referrals from 1,600+ clinicians across Australia.
Fortrea und Omico kooperieren zur Förderung der biomarkergestützten Entwicklung von Krebsmedikamenten
Fortrea, a leading global clinical research organization, has partnered with Omico, Australia's leading precision oncology screening organization, to accelerate biomarker-driven cancer drug development. The collaboration combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve study planning, patient recruitment, and access to biomarker-based clinical trials in Australia, leveraging Omico's database of over 23,000 patients and referrals from 1,600+ Australian physicians.